Offline Showroom in USA
Post Offer Free

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Digestive System Drugs API  > Tesofensine CAS 402856-42-2 NS-2330

Tesofensine CAS 402856-42-2 NS-2330 

Payment Terms: T/T,L/C,WU 
Place of Origin: Shandong, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C17H23Cl2NO
Production Capacity: 1000kg/month
Delivery Date: within 7 days
Formula: C17H23Cl2NO
Content: 99%
CAS: 402856-42-2
Boiling point: 396.629°C at 760 mmHg
Means of Transport: Ocean,Land,Air
Packing: According to customer requi...
Mol. mass: 328.277 g/mol
Appearance: White or almost white, crys...
Density: 1.162g/cm3
Flashing point: 193.675°C

The most commonly reported side effects in the obese population were dry mouth, headache, nausea, insomnia, diarrhoea and constipation.

Tesofensine (CAS:402856-42-2)

Item Specification Result
Appearance White or almost white, crystalline powder Complies

Related substance (HPLC)

Total impurity ≤0.5%

Max single impurity ≤0.1%



Odor  CharacteristicComplies
Assay  99%99.8%
Sieve analysis  100% pass 80 meshComplies

Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of medicine, which is being developed for the treatment of obesity. The right to develop and market tesofensine is held by NeuroSearch, a Danish pharmaceutical company.


Metabolism and t½

Tesofensine has a long half-life of about 9 days (220 h) and is mainly metabolized by cytochrome P4503A4 (CYP3A4) to the N-normethyl-metabolite NS2360.[7][8] NS2360 is the only metabolite detectable in human plasma. It has a longer half-life than tesofensine, i.e. approximately 16 days (374 h) in humans, and has an exposure of 31–34% of the parent compound at steady state. In vivo data indicate that NS2360 is responsible for approximately 6% of the activity of tesofensine. As in animals, the kidney appears to play only a minor role in the clearance of tesofensine in humans (about 15–20%).

Adverse events

In general, the safety profile of tesofensine is similar to currently approved medications for the treatment of obesity. The most commonly reported side effects in the obese population were dry mouth, headache, nausea, insomnia, diarrhoea and constipation. A dose-dependent pattern was observed for dry mouth and insomnia. The overall withdrawal rate due to adverse events in clinical trials in the obese population was 13% with tesofensine and 6% with placebo. Blood pressure and heart rate increases with the therapeutically relevant doses of tesofensine (0.25 mg and 0.5 mg) were 1–3 mmHg and up to 8 bpm, respectively.

Tesofensine very effective for central obesity. Another study shows that low doses of SuoFenXin obesity treatment is safe and effective.


skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on

Company Info


Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: